← All trials
NCT07083154
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2025
- Primary completion
- Aug 1, 2029
- Completion date
- Aug 1, 2029
- First posted
- Jul 24, 2025
- Last posted
- Nov 21, 2025
- Enrollment
- 420
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing UniversityLead sponsor
- Changzhou No.2 People's HospitalCollaborator
- Nanjing Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Nanjing UniversitySponsor investigator
- Jiao Tong UniversityCollaborator
- Central South UniversityCollaborator
- Fudan UniversityCollaborator
- Nanjing UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.